Faisal Alrai

25/03/2026

Water treatment plant design consideration

The biggest mistake you can make in RO installation is when you start designing without fully understanding every aspect of the system...
In this post, we'll talk about common design mistakes that can ruin a plant from day one, and that unfortunately, many people make!

To avoid mistakes you have to follow the tips that shall be considered in the design of WTP:

1. Water Analysis

Many people design an RO plant assuming a TDS of 2,000 ppm, for example!
But when you look at the reality, you find that:

· 75 ppm silica
· Very high calcium sulfate
· pH is higher than 8
· Higher than normal magnesium
· Or even bacteria and microorganisms in the raw water.

The result?

1. Silica buildup in the membranes is unavoidable, even with CIP.
2. Scaling from the first month.
3. Rejection is not constant, and pressure increases rapidly.
4. The plant loses performance in less than 6 months.

The solution?
A comprehensive water analysis is required before any design. Everything should be analyzed:

· TDS
· SDI
· pH
· Hardness
· Iron / Manganese
· Bacteria count
· Turbidity
· TOC if the water will be used in the Pharma industries.



2. Pre-treatment is weak or not calculated correctly.

Some people think that an RO system will work with any water. Will not work properly.
Without proper pre-treatment, you'll be paying for new membranes every month.

The most common mistakes in pre-treatment:

1. Insufficient filtration media (sand, carbon, or a mixture)

2. Dosing is not present or not accurately calculated (antiscalant/acid/chlorine)

3. Final filtration is not accurate (lack of 5 microns or added after dosing)

4. Neglecting to remove iron and manganese from the water

Solution?
Design pre-treatment precisely based on the water type, and separate the following steps carefully:
· Media filter > Carbon filter > Cartridge filter
· Dosing skid with precise calculations and pulse-operated pumps
· Many times we need a softener or even ultrafiltration before RO in some cases.


3. Improper Pressure and Flow Design

Many people who design a plant, and discover that :
The high-pressure pump is unable to achieve the required flow rate. i.e. If you designed the feed to be 15 m³/hour, but the recovery is very high, causing the TDS to drop.

This error leads to:
1. Overpressure on the membranes.
2. Decreases in salt rejection efficiency.
3. The fouling rate increases rapidly.

Advice?
To build a balanced system, design software shall be used.

Some of the Design Software are :
· Hydranautics IMS Design
· Toray DS
· Wave- DOW/FilmTec)
· ROSA
· LewaPlus (pre/post-treatment)
· Lanxess RO & IX Design Software

*Don't forget the flow meter on each stream for monitoring.


4. (CIP) system design is incomplete or completely absent.

Several people design an RO plant for thousands of USD excluding a CIP unit!
So how do you clean the membranes?

Common CIP mistakes:

1. There is no heater/ heat exchanger included in the CIP System (the chemicals need a specific temperature)
2. The CIP tank is too small or made of ordinary stainless steel, which reacts with the chemicals
3. The pump is weak and doesn't reach the required pressure
4. No flow direction control during cleaning (flow reversal)

Solution?

· Water temp. shall be more than 70°C
· Use Suitable materials for chemicals (PP or HDPE)
· CIP pump
· Bi-directional cleaning line design


5. Poorly planned electrical system

Many times, the HP pump needs a soft starter or VFD, but the designer doesn't provide one. Or the PLC isn't protected by a battery or UPS, and as soon as the power goes out, the plant restarts incorrectly.

Result?

1. Motor burn
2. Electrical surge in the control panel
3. Pump cavitation or sudden stop

Solution?

The following components shall be installed in the system :

· VFD for the main pump
· UPS for the PLC
· Interlock between starting and dosing
· Sensors for low pressure / high pressure/conductivity protection

19/03/2026

08/11/2025

The R-LAF System and Its Importance in the Pharmaceutical Industry

The Reverse Laminar Flow (R-LAF) system plays a vital role in the pharmaceutical, chemical, and biological industries, especially during processes such as sampling or material preparation. This system provides a clean and controlled environment by directing airflow in a specific direction to prevent the spread of particles and ensure they remain within the work area.

How the R-LAF System Works:
Reverse Airflow: Fresh air flows continuously from the top or sides, downwards, or horizontally.

High-Efficiency Filtration: Air passes through HEPA filters with 99.97% efficiency, removing particles as small as 0.3 microns.

Particle Containment: During processes, generated particles are absorbed within the system and prevented from escaping.

Differential Pressure: The system maintains negative pressure to ensure no contaminants escape.

Where is the R-LAF System Used?

1. 1. Sampling of Raw Materials and Packaging Materials: Provides a sterile and safe environment for accurate sampling.

2. Weighing and Dispensing: Protects the operator and prevents contamination during raw material handling.

3. Aseptic Processes: Used in cleanrooms to maintain complete sterility.

Key Features of the R-LAF System:

• HEPA Filters: Ensures clean, particle-free air.

• Pressure Gauge: Monitors pressure differentials to ensure proper system operation.

• UV Sterilization System (depending on the system): For sterilizing the work area.

• Unidirectional Airflow: Prevents cross-contamination between different materials.

Conclusion: The R-LAF system provides a clean and controlled environment, essential for meeting Good Manufacturing Practice (GMP) requirements in the pharmaceutical industry. In addition to protecting the product, it also protects personnel and the surrounding environment, ensuring workflow with the highest levels of safety and efficiency.

06/09/2025

06/09/2025

CIP (Clean-in-Place) Vs. SIP ( Sterilize - in - Place)..

In sterile pharmaceutical production, CIP (Clean-in-Place) is an automated process using chemicals and rinses to remove product residues and contaminants, while SIP (Sterilize-in-Place) is a distinct, follow-up process that uses pressurized steam to achieve a high level of microbial decontamination and ensure true sterility. Both methods are crucial for maintaining product quality, preventing cross-contamination, ensuring operator and product safety, and meeting strict regulatory requirements by cleaning and sterilizing equipment without the need for disassembly.

CIP (Clean-in-Place)
* Purpose: �To remove residual product, microbial deposits, and other contaminants from the internal surfaces of equipment. ��
* Process: �Involves a sequence of steps using hot water, detergents (such as caustic or acidic solutions), and rinsing to clean the system thoroughly. ��
* Outcome: �Achieves effective, reproducible cleaning standards that reduce residues to specified toxicological and microbiological limits. ��
SIP (Sterilize-in-Place)
* Purpose: �To kill microorganisms, including bacteria, fungi, viruses, and spores, to a defined sterility assurance level (SAL). ��
* Process: �Follows CIP and uses the thermal energy of condensing saturated steam circulated through the system. ��
* Outcome: �Achieves validated sterility, ensuring the equipment is free from viable microorganisms for sterile pharmaceutical production. ��
Why are they essential in pharmaceutical production?
* Hygiene and Quality: �Critical for guaranteeing product quality and preventing contamination, especially in multi-purpose plants. �
* Regulatory Compliance: �Essential for meeting regulatory standards and for validation and documentation processes. �
* Efficiency: �Automation eliminates time-consuming manual disassembly and reassembly, speeding up product changeovers and reducing downtime. �
* Safety: �Protects operators from exposure to potent or toxic substances and ensures product safety. �
* Reproducibility: �The automated nature of the processes ensures consistent and reproducible hygiene standards every time.

CIP (Clean-in-Place) durations vary but can be 60-90 minutes to a few hours for optimized cycles, focusing on chemical cleaning and rinsing.

SIP (Sterilize-in-Place) durations are typically shorter, with an exposure stage of 20-40 minutes at high temperatures (121-134°C) after equipment has been brought to temperature.
The exact durations for both processes are validated and specific to the equipment design, product, and regional regulations

26/07/2025

316 L St. Steel Surface Roughness and Standards for Pharma Use:

ASME BPE for Stainless Steel in Pharma Surface roughness (Ra) plays a significant role in ensuring the cleanliness and sterility of pharmaceutical equipment. According to the ASME BPE-2024 (Bioprocessing Equipment) Standard [1], surface roughness directly impacts the ability of surfaces to resist bacterial growth and biofilm formation, particularly in high-purity environments such as cleanrooms and sterile filling areas. ASME BPE specifies different roughness levels depending on the application.
Mechanical polish (MP), widely used in standard pharmaceutical processes, generally results in roughness values of:
* Ra ≤ 0.50 μm (20 μin) for non-critical areas.
* Ra ≤ 0.38 μm (15 μin) for surfaces that come into direct contact with the product.
For applications requiring ultra-high purity, such as biotechnology and parenteral drug production, electropolishing is essential. This process further reduces the roughness to:
* Ra ≤ 0.38 μm (15 μin) as a standard [15].
* In extreme cases, surfaces can reach Ra ≤ 0.25 μm (10 μin), which is critical for environments where even the smallest surface imperfections could harbor contaminants.
The smoother the surface, the easier it is to clean, which directly influences
CIP (Clean-In-Place) efficiency, reducing cleaning times and improving process turnaround. Additionally, smoother surfaces minimize the risk of contamination during sterilization, which is a core requirement for pharmaceutical processes governed by FDA regulations.

Surface Treatments for AISI 316L Components in Pharma

1. Electropolishing
Electropolishing is a crucial step in surface preparation for pharmaceutical applications. The process smooths microscopic peaks and valleys on the metal surface, improving its corrosion resistance and making it easier to sterilize.
Standard electropolishing conditions for AISI 316L involve a current density of 0.1-0.3 A/cm² in a sulfuric and phosphoric acid bath, which removes up to 50 µm of material and reduces surface roughness to Ra ≤ 0.4 µm.

2. Passivation: Enhancing Corrosion Resistance
Post-electropolishing, the passivation process is essential to remove any remaining free iron from the surface, thereby enhancing the natural chromium oxide layer that protects against corrosion. Passivation for AISI 316L typically involves immersion in a nitric acid solution (20-25% concentration) at temperatures of 50-60°C for 30-45 minutes, following ASTM A967 guidelines.
The passivated surface meets the strict requirements for corrosion resistance in pharmaceutical processes, including compliance with ASME BPE 2024 and GMP standards.

3. Alternative Surface Treatments
In addition to electropolishing and passivation, coatings like PTFE or PVD are used in applications where low friction or enhanced wear resistance is required. For example, in dynamic systems such as valves or mixers, PTFE coatings can significantly reduce the risk of surface damage and contamination.
Regulatory Requirements and Surface Finishing Standards

1. Compliance with ASME BPE-2024 and GMP Standards
Both surface treatments and machining processes for AISI 316L components must comply with the ASME BPE-2024 standards, which define acceptable surface finishes, tolerances, and material traceability. The standard emphasizes maintaining Ra values below 0.5 µm for product contact surfaces, and passivation is mandated for components that undergo repeated sterilization cycles. Also, the FDA's GMP requirements specify that all treatments must be fully documented and traceable, ensuring quality control throughout the manufacturing process

References:
1. ASME BPE 2024. Bioprocessing Equipment Standard, 2024.
2. ISO 10993-1. Biological evaluation of medical devices – Part 1: Evaluation and testing within a risk management process, 2018.
3. FDA. Pharmaceutical GMPs for the 21st Century – A Risk-Based Approach, 2004.
4. Brindley, D. "Passivation of Stainless Steel in Pharmaceutical Applications." Journal of Bioprocess Engineering, 2017.